A semi-mechanistic model of the relationship between average glucose and HbA1c in healthy and diabetic subjects

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 40, Issue 2, 2013, Pages 129-142

  Lledó García, Rocío ^a,c   Mazer, Norman A ^b   Karlsson, Mats O ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c Department of Modeling and Simulation ^*  (United Kingdom)

Author keywords

Average glucose concentration; Diabetes; Glycosylation; HbA1c; Mechanism based model; PD; Pharmacometrics

Indexed keywords

GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C;

ARTICLE; CALCULATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIABETES MELLITUS; ERYTHROCYTE LIFESPAN; ERYTHROID PRECURSOR CELL; GLYCOSYLATION; HEMOGLOBIN DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; MATHEMATICAL COMPUTING; PRIORITY JOURNAL; SEMI MECHANISTIC MODEL; STOCHASTIC MODEL; VALIDATION PROCESS;

BLOOD GLUCOSE; DIABETES MELLITUS; ERYTHROCYTES; GLUCOSE; GLYCOSYLATION; HEMOGLOBIN A, GLYCOSYLATED; HUMANS;

EID: 84880702422     PISSN: 1567567X     EISSN: 15738744     Source Type: Journal    
DOI: 10.1007/s10928-012-9289-6     Document Type: Article

References (46)

1. Svendsen PA, Lauritzen T, Soegaard U, Nerup J (1982) Glycosylated haemoglobin and steady-state mean blood glucose concentration in Type 1 (insulin-dependent) diabetes. Diabetologia 23(5):403-405
2. Goldstein DE, Little RR, Lorenz RA, Malone JI, Nathan DM, Peterson CM (2004) Tests of glycemia in diabetes. Diabetes Care 27(Suppl 1):S91-S93
3. Nathan DM, Turgeon H, Regan S (2007) Relationship between glycated haemoglobin levels and mean glucose levels over time. Diabetologia 50(11):2239-2244
4. Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ (2008) Translating the A1C assay into estimated average glucose values. Diabetes Care 31(8):1473-1478
5. Nathan DM, Singer DE, Hurxthal K, Goodson JD (1984) The clinical information value of the glycosylated hemoglobin assay. N Engl J Med 310(6):341-346
6. International Expert Committee (2009) International Expert Committee Report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 32(7):1327-1334
7. Jeffcoate SL (2004) Diabetes control and complications: the role of glycated haemoglobin, 25 years on. Diabet Med 21(7):657-665
8. Weykamp C, John WG, Mosca A (2009) A review of the challenge in measuring hemoglobin A1c. J Diabetes Sci Technol 3(3):439-445
9. Hoelzel W, Weykamp C, Jeppsson JO, Miedema K, Barr JR, Goodall I, Hoshino T, John WG, Kobold U, Little R, Mosca A, Mauri P, Paroni R, Susanto F, Takei I, Thienpont L, Umemoto M, Wiedmeyer HM (2004) IFCC reference system for measurement of hemoglobin A1c in human blood and the national standardization schemes in the United States, Japan, and Sweden: a method-comparison study. Clin Chem 50(1):166-174
10. Jeppsson JO, Kobold U, Barr J, Finke A, Hoelzel W, Hoshino T, Miedema K, Mosca A, Mauri P, Paroni R, Thienpont L, Umemoto M, Weykamp C (2002) Approved IFCC reference method for the measurement of HbA1c in human blood. Clin Chem Lab Med 40(1):78-89
11. Sacks DB (2005) Global harmonization of hemoglobin A1c. Clin Chem 51(4):681-683
12. IFCC working group (2011) IFCC standardization of HbA1c. http://www.ngsp.org/ifccrs.asp. Accessed Nov 2012
13. Cohen RM, Franco RS, Khera PK, Smith EP, Lindsell CJ, Ciraolo PJ, Palascak MB, Joiner CH (2008) Red cell life span heterogeneity in hematologically normal people is sufficient to alter HbA1c. Blood 112(10):4284-4291
14. Peterson CM, Jones RL, Dupuis A, Levine BS, Bernstein R, O'Shea M (1979) Feasibility of improved blood glucose control in patients with insulin-dependent diabetes mellitus. Diabetes Care 2(4):329-335
15. Hempe JM, Gomez R, McCarter RJ Jr, Chalew SA (2002) High and low hemoglobin glycation phenotypes in type 1 diabetes: a challenge for interpretation of glycemic control. J Diabetes Complicat 16(5):313-320
16. Osterman-Golkar SM, Vesper HW (2006) Assessment of the relationship between glucose and A1c using kinetic modeling. J Diabetes Complicat 20(5):285-294
17. Gisleskog PO, Karlsson MO, Beal SL (2002) Use of prior information to stabilize a population data analysis. J Pharmacokinet Pharmacodyn 29(5-6):473-505
18. Willekens FL, Roerdinkholder-Stoelwinder B, Groenen-Dopp YA, Bos HJ, Bosman GJ, van den Bos AG, Verkleij AJ, Werre JM (2003) Hemoglobin loss from erythrocytes in vivo results from spleen-facilitated vesiculation. Blood 101(2):747-751
19. Leitch JM, Carruthers A (2007) ATP-dependent sugar transport complexity in human erythrocytes. Am J Physiol Cell Physiol 292(2):C974-C986
20. Uehlinger DE, Gotch FA, Sheiner LB (1992) A pharmacodynamic model of erythropoietin therapy for uremic anemia. Clin Pharmacol Ther 51(1):76-89
21. Hamren B, Bjork E, Sunzel M, Karlsson M (2008) Models for plasma glucose, HbA1c, and hemoglobin interrelationships in patients with type 2 diabetes following tesaglitazar treatment. Clin Pharmacol Ther 84(2):228-235
22. de Winter W, DeJongh J, Post T, Ploeger B, Urquhart R, Moules I, Eckland D, Danhof M (2006) A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying type 2 diabetes mellitus. J Pharmacokinet Pharmacodyn 33(3):313-343
23. Lledó-García R, Kalicki RM, Uehlinger DE, Karlsson MO (2012) Modeling of red blood cell life-spans in hematologically normal populations. J Pharmacokinet Pharmacodyn 39(5):453-462
24. Virtue MA, Furne JK, Nuttall FQ, Levitt MD (2004) Relationship between GHb concentration and erythrocyte survival determined from breath carbon monoxide concentration. Diabetes Care 27(4):931-935
25. Ribbing J, Hamren B, Svensson MK, Karlsson MO (2010) A model for glucose, insulin, and beta-cell dynamics in subjects with insulin resistance and patients with type 2 diabetes. J Clin Pharmacol 50(8):861-872
26. Nuttall FQ, Gannon MC, Swaim WR, Adams MJ (2004) Stability over time of glycohemoglobin, glucose, and red blood cell survival in hematologically stable people without diabetes. Metabolism 53(11):1399-1404
27. Beach KW (1979) A theoretical model to predict the behavior of glycosylated hemoglobin levels. J Theor Biol 81(3):547-561
28. Higgins P, Bunn F (1981) Kinetic analysis of the nonenzymatic glycosylation of hemoglobin. J Biol Chem 256(10):5204-5208
29. Mortensen HB, Volund A, Christophersen C (1984) Glucosylation of human haemoglobin A. Dynamic variation in HbA1c described by a biokinetic model. Clin Chim Acta 136(1):75-81
30. Ladyzynski P, Wojcicki JM, Bak M, Sabalinska S, Kawiak J, Foltynski P, Krzymien J, Karnafel W (2008) Validation of hemoglobin glycation models using glycemia monitoring in vivo and culturing of erythrocytes in vitro. Ann Biomed Eng 36(7):1188-1202
31. Jonsson EN, Karlsson MO (1999) Xpose - an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 58(1):51-64
32. Karlsson, MO, Holford, NH (2008) Tutorial on visual predictive checks http://www.page-meeting.org/?abstract=1434. PAGE, Marseille. Accessed Nov 2012
33. Nuttall FQ (1998) Comparison of percent total GHb with percent HbA1c in people with and without known diabetes. Diabetes Care 21(9):1475-1480
34. Strocchi A, Schwartz S, Ellefson M, Engel RR, Medina A, Levitt MD (1992) A simple carbon monoxide breath test to estimate erythrocyte turnover. J Lab Clin Med 120(3):392-399
35. Wilson DM, Kollman (2008) Relationship of A1C to glucose concentrations in children with type 1 diabetes: assessments by high-frequency glucose determinations by sensors. Diabetes Care 31(3):381-385
36. Peterson CM, Jones RL, Koenig RJ, Melvin ET, Lehrman ML (1977) Reversible hematologic sequelae of diabetes mellitus. Ann Intern Med 86(4):425-429
37. Kamada T, McMillan DE, Yamashita T, Otsuji S (1992) Lowered membrane fluidity of younger erythrocytes in diabetes. Diabetes Res Clin Pract 16(1):1-6
38. Rattan V, Shen Y, Sultana C, Kumar D, Kalra VK (1997) Diabetic RBC-induced oxidant stress leads to transendothelial migration of monocyte-like HL-60 cells. Am J Physiol 273(2 Pt 1):E369-E375
39. Bunn HF, Haney DN, Kamin S, Gabbay KH, Gallop PM (1976) The biosynthesis of human hemoglobin A1c. Slow glycosylation of hemoglobin in vivo. J Clin Invest 57(6):1652-1659
40. Khera PK, Joiner CH, Carruthers A, Lindsell CJ, Smith EP, Franco RS, Holmes YR, Cohen RM (2008) Evidence for interindividual heterogeneity in the glucose gradient across the human red blood cell membrane and its relationship to hemoglobin glycation. Diabetes 57(9):2445-2452
41. Mortensen HB, Christophersen C (1983) Glucosylation of human haemoglobin a in red blood cells studied in vitro. Kinetics of the formation and dissociation of haemoglobin A1c. Clin Chim Acta 134(3):317-326
42. Mortensen HB, Christophersen C (1993) The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. J Med N Engl 329(14):977-986
43. Panteghini M, John WG (2007) Implementation of haemoglobin A1c results traceable to the IFCC reference system: the way forward. Clin Chem Lab Med 45(8):942-944
44. Weykamp C, John WG, Mosca A, Hoshino T, Little R, Jeppsson JO, Goodall I, Miedema K, Myers G, Reinauer H, Sacks DB, Slingerland R, Siebelder C (2008) The IFCC Reference Measurement System for HbA1c: a 6-year progress report. Clin Chem 54(2):240-248
45. International Federation of Clinical Chemistry and Laboratory Medicine, IFCC Scientific Division, Mosca A, Goodall I, Hoshino T, Jeppsson JO, John WG, Little RR, Miedema K, Myers GL, Reinauer H, Sacks DB, Weykamp CW (2007) Global standardization of glycated hemoglobin measurement: the position of the IFCC Working Group. Clin Chem Lab Med 45(8):1077-1080
46. Woo S, Krzyzanski W, Duliege AM, Stead RB, Jusko WJ (2008) Population pharmacokinetics and pharmacodynamics of peptidic erythropoiesis receptor agonist (ERA) in healthy volunteers. J Clin Pharmacol 48(1):43-52